Paragon Private Wealth Management LLC Purchases 606 Shares of Eli Lilly and Company $LLY

Paragon Private Wealth Management LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 28.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,712 shares of the company’s stock after acquiring an additional 606 shares during the quarter. Eli Lilly and Company makes up about 0.9% of Paragon Private Wealth Management LLC’s investment portfolio, making the stock its 21st largest position. Paragon Private Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,914,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new position in Eli Lilly and Company in the second quarter worth about $356,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $749,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 0.5%

NYSE LLY opened at $1,143.29 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market capitalization of $1.08 trillion, a PE ratio of 40.61, a P/E/G ratio of 1.26 and a beta of 0.53. The company has a fifty day moving average of $984.90 and a 200 day moving average of $1,014.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive Phase 3 data for retatrutide showed strong weight-loss results and benefits for obesity-related conditions, boosting expectations that Lilly can extend its lead in the GLP-1/obesity market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: New data on Lilly’s oral GLP-1 Foundayo (orforglipron) showed superior A1C control and weight loss versus oral semaglutide in type 2 diabetes trials, and additional analyses highlighted weight-loss benefits for women across menopausal stages. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: The FDA approved an every-eight-weeks maintenance dosing regimen for EBGLYSS in moderate-to-severe atopic dermatitis, which could improve convenience and support adoption in Lilly’s dermatology franchise. PR Newswire: FDA approves Lilly’s EBGLYSS every eight weeks
• Positive Sentiment: Lilly also expanded its Alzheimer’s pipeline through a collaboration with AlzeCure Pharma for global rights to ACD680, adding optionality beyond obesity and diabetes. Yahoo Finance: Eli Lilly Expands Alzheimer’s Pipeline With AlzeCure Deal
• Neutral Sentiment: Broader sector rotation into healthcare and defensive stocks is also helping sentiment around Lilly as investors pull back from tech and AI names. Investopedia: As Tech Stocks Slide, The Healthcare Sector Shines

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research report on Tuesday, February 10th. Bank of America increased their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.